Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02594111 · ClinicalTrials.gov registry record · Phase 4
Colchicine in Percutaneous Coronary Intervention
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 714
- Enrollment target
NCT02594111: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT02594111 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 714 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (38% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02594111, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 714 participants
- Enrollment target
Study Summary
Inflammation in the arteries of the heart may increase the risk of cardiac death. The proposed research seeks to identify the potential beneficial role of a safe anti-inflammatory medication, colchicine, on reducing damage caused by opening up a blockage in the arteries of the heart. With its quick onset of action and excellent safety profile, colchicine may have the potential to reduce risk of major adverse events related to the heart. This research also seeks to better understand the role of neutrophils, the most common type of inflammatory white blood cell in the body, when there is damage to the heart.
Primary Outcome
troponin above the upper limit of normal (ULN)
Interventions
- DRUG Colchicine vs Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2013-05-30 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 4 |
What the finished NCT02594111 record still lists
NCT02594111 is an interventional study that assigns participants to a tested intervention. The registered 714 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (38% higher).
The record links to 0 conditions, and to 1 intervention - of which Colchicine vs Placebo is the first listed.
NCT02594111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02594111 about?
NCT02594111 is a clinical study titled "Colchicine in Percutaneous Coronary Intervention". Inflammation in the arteries of the heart may increase the risk of cardiac death. The proposed research seeks to identify the potential beneficial role of a safe anti-inflammatory medication, colchicine, on reducing damage caused by opening up a blockage in the arteries of the heart. With its quick ...
What is the current status of trial NCT02594111?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 714 participants. The study started on 2013-05-30. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02594111?
The interventions under investigation include: Colchicine vs Placebo (DRUG).
Who is sponsoring clinical trial NCT02594111?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02594111's enrollment target sits among peer trials
714 114th of 2000 higher than 1,887 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI